샘플 요청 목록

 카트 문의
시장보고서
상품코드
1733498

세계의 의약품 재이용 시장

Drug Repurposing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 377 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

의약품 재이용 세계 시장은 2030년까지 373억 달러에 이를 전망

2024년에 294억 달러로 추정된 의약품 재이용 세계 시장은 2024-2030년 분석 기간에서 CAGR 4.1%로 성장하여 2030년에는 373억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 '암 치료'는 CAGR 4.4%를 나타내고, 분석 기간 종료시에는 203억 달러에 이를 것으로 예측됩니다. CNS Diseases Indication(중추신경계 질환) 부문은 분석 기간중 CAGR 4.3%로 성장한다고 추정됩니다.

미국 시장은 80억 달러로 추정, 중국은 CAGR 7.5%로 성장 예측

미국의 의약품 재이용 시장은 2024년에 80억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 76억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.5%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.6%와 3.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.4%로 전망됩니다.

세계의 의약품 재이용 시장-주요 동향과 촉진요인 정리

의약품의 재사용이 현대의 치료제로 다시 주목받는 이유는 무엇일까?

의약품 재사용은 약물 재포지셔닝(Drug Repositioning)이라고도 불리며, 기존 의약품이나 이전에 보류되었던 의약품의 새로운 치료 용도를 찾아내는 것을 의미합니다. 이 접근법은 제약사, 연구자, 보건 당국이 미충족 의료 수요에 대응하기 위해 보다 신속하고 비용 효율적인 방법을 모색하면서 르네상스 시대를 맞이하고 있습니다. 기존 의약품 개발에는 10년 이상의 시간과 수십억의 비용이 소요되며, 임상적으로 실패하는 비율도 높습니다. 반면, 리퍼포즈 의약품은 이미 안전성과 약동학의 중요한 장애물을 통과했기 때문에 개발자는 초기 단계의 시험을 피하고 시판까지 걸리는 시간을 크게 단축할 수 있습니다. 이 때문에 리퍼포즈는 특히 희귀질환, 종양학, 신경퇴행성 질환, 감염성 질환 등의 분야에서 매우 매력적인 전략이 되고 있습니다.

코로나19 팬데믹은 렘데시비르, 덱사메타손, 하이드 록시 클로로퀸과 같은 약물이 SARS-CoV-2에 대한 효능을 신속하게 평가받으면서 리퍼포즈에 대한 관심을 더욱 높였습니다. 이 위기는 규제 당국이 긴급사용승인(EUA)을 통해 재창출 의약품을 신속하게 진행할 수 있는 방법을 보여줌으로써 가속화된 경로의 새로운 선례를 보여주었습니다. 또한, 살리도마이드(다발성 골수종 치료제로 재도입)와 실데나필(원래 고혈압 치료제로 개발되어 현재 발기부전 치료제로 널리 사용되고 있음)과 같은 의약품의 성공은 이 전략이 광범위한 임상적, 상업적 가치를 가지고 있음을 입증했습니다. 이러한 사례는 의약품 재사용이 현대 의약품 연구 및 개발에서 필수적인 요소로 간주되는 이유를 강조합니다.

의약품 재사용을 변화시키는 새로운 트렌드는 무엇일까?

리파포징 시장을 재편하는 가장 큰 트렌드는 인공지능(AI)과 머신러닝(ML)을 신약개발 파이프라인에 통합하는 것입니다. 계산 모델은 유전체 데이터에서 실제 증거 및 전자 의료 기록에 이르기까지 방대한 데이터 세트를 분석하여 새로운 약물-질병 관계를 식별할 수 있게 되었으며, AI 기반 플랫폼은 화합물 라이브러리의 비실리콘 스크리닝을 가능하게 하고, 전임상 및 임상 평가를 위한 후보물질의 우선순위를 정할 수 있습니다. 이는 특히 희귀질환 치료와 정밀 종양학 분야에서 큰 효과를 발휘할 수 있습니다. 희귀질환 치료 및 정밀 종양학 분야는 환자 수가 제한적이고 연구개발비용이 높아 기존 파이프라인에서 어려움을 겪는 경우가 많습니다.

NIH의 NCATS(National Center for Advancing Translational Sciences)나 Open Targets와 같은 이니셔티브는 학계, 산업계, 정부 간의 데이터와 자원을 공유하고 재사용하기 위한 노력을 가속화하고 있습니다. 자원을 공유하여 재사용 노력을 가속화하고 있습니다. 또한, 블록버스터 의약품의 특허가 만료됨에 따라 제네릭 의약품과 전문 제약회사들의 재창출에 대한 관심이 높아지고 있습니다. 미국에서는 505(b)(2) 승인에 대한 명확한 지침을 제공하는 노력이, 유럽에서는 적응형 라이선싱 모델이 지적재산권 및 임상 검증 상황을 보다 쉽게 탐색할 수 있도록 하는 등 규제 환경도 변화하고 있습니다. 이러한 추세는 혁신, 협업, 그리고 질병 영역 전반에 걸친 의약품 개발을 가속화할 수 있는 비옥한 토양을 조성하고 있습니다.

리퍼포즈 전략의 혜택을 가장 많이 받는 치료 영역은?

의약품 재사용의 영향은 복잡하고 충분한 치료를 받지 못하는 치료 영역에서 가장 두드러지게 나타납니다. 예를 들어, 암 분야에서는 보조제나 2차 치료제로 재창출 의약품이 검토되고 있습니다. 메트포르민(당뇨병 치료제), 프로프라놀롤(베타차단제), 이트라코나졸(항진균제)은 다양한 연구에서 항암제로서의 가능성을 보여주고 있습니다. 알츠하이머병이나 파킨슨병과 같은 신경퇴행성 질환에서는 염증, 콜레스테롤 대사, 미토콘드리아 기능을 표적으로 하는 약물이 새로운 치료제가 어려움을 겪고 있는 질환의 진행을 늦추기 위해 재배치되고 있습니다. 이 리퍼포징 모델은 알려진 약력학을 활용하여 이차적인 경로를 표적으로 삼음으로써 실패가 많은 영역에서 새로운 희망을 제시합니다.

감염, 특히 항균제 내성(AMR)이 증가함에 따라 재창출된 항바이러스제 및 항생제가 중요한 틈새를 메우고 있습니다. 예를 들어, 일부 항암제는 예상치 못한 항균 및 항진균 작용을 나타내며, 정신과 치료제는 바이러스 감염에서 면역 조절의 역할을 연구하고 있습니다. 또한 루푸스, 류마티스 관절염, 다발성 경화증과 같은 자가면역질환 및 염증성 질환도 다른 질환과의 중복 경로가 조사되면서 그 혜택을 받을 수 있습니다. 정신 건강 치료에서도 치료 저항성 우울증에 케타민을 사용하는 것이 대표적인 예입니다. 이러한 치료 분야 간 응용은 많은 레거시 의약품의 가치 제안을 확장하고 현대 치료 패러다임으로 재통합을 촉진하고 있습니다.

의약품 재사용의 성장과 전략적 투자의 원동력은?

의약품 재창출 시장의 성장은 기술 활성화, 규제 완화, 진화하는 제약 전략과 관련된 여러 요인에 의해 주도되고 있으며, AI와 바이오인포매틱스 플랫폼은 작용 메커니즘을 예측하고 표적 외 효과를 정확하게 식별함으로써 재창출 프로젝트의 성공률을 크게 향상시키고 있습니다. 리포포징 프로젝트의 성공률을 크게 향상시키고 있습니다. 오믹스 프로파일, 질병 등록, 환자 수준 데이터 등 대규모 생물의학 데이터 세트의 가용성은 교차 적응증 매핑 및 약물 효능 모델링을 위한 비옥한 토양을 제공합니다. 이러한 기술은 기존 신약 개발의 위험, 비용, 시간을 줄여주는 역할을 합니다.

최종 용도로의 채택도 가속화되고 있습니다. 생명공학 기업들은 리파포징을 핵심 비즈니스 모델로 추구하는 경향이 강화되고 있으며, 대형 제약사들은 특허가 만료되거나 성능이 낮은 자산의 가치를 확대하기 위해 리파포징을 라이프사이클 관리에 통합하고 있습니다. 규제 당국은 미국의 505(b)(2) 경로와 같은 간소화된 승인 경로를 도입하고 있으며, 개발자는 기존 안전성 및 유효성 데이터를 활용할 수 있는 반면, 새로운 적응증에 대해서는 보완적인 임상적 증거만 요구하고 있습니다. 따라서 라이선싱, 합작투자, 벤처캐피털에 의한 리퍼포밍 사업에 대한 투자가 용이하게 이루어질 수 있는 환경이 조성되어 있습니다. 또한, 환자 옹호 단체와 희귀질환 재단의 로비 활동과 리퍼포밍 연구에 대한 자금 지원을 통해 인지도와 임상적 모멘텀을 높이고 있습니다. 이러한 힘들이 합쳐져 의약품 재창출은 세계 제약 혁신 생태계에서 전략적으로 빠르게 성장하는 핵심 분야로 자리매김하고 있습니다.

부문

적응 질환(암, 중추신경계 질환, 신경 퇴행성 질환, 기타 적응 질환), 접근 유형(질환 중심 접근, 표적 중심 접근, 약제 중심 접근), 최종 사용(병원 및 진료소, 외래 수술 질환, 기타 최종 사용)

조사 대상 기업 예(주요 41개사)

  • AbbVie Inc.
  • Algernon Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • BioXcel Therapeutics Inc.
  • Bristol-Myers Squibb Co.
  • Every Cure
  • Exscientia Ltd.
  • GSK plc
  • Healx Ltd.
  • Johnson & Johnson
  • Melior Discovery
  • Novartis AG
  • Pfizer Inc.
  • Rejuvenate Biomed NV
  • Retrotope Inc.
  • SOM Biotech S.L.
  • Tonix Pharmaceuticals
  • United Therapeutics Corp.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국의 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량경제 상황에서 이 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.10

Global Drug Repurposing Market to Reach US$37.3 Billion by 2030

The global market for Drug Repurposing estimated at US$29.4 Billion in the year 2024, is expected to reach US$37.3 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Oncology Indication, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$20.3 Billion by the end of the analysis period. Growth in the CNS Diseases Indication segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.0 Billion While China is Forecast to Grow at 7.5% CAGR

The Drug Repurposing market in the U.S. is estimated at US$8.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.6 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Drug Repurposing Market - Key Trends & Drivers Summarized

Why Is Drug Repurposing Gaining Renewed Attention in Modern Therapeutics?

Drug repurposing-also known as drug repositioning-involves identifying new therapeutic uses for existing or previously shelved drugs. This approach is experiencing a renaissance as pharmaceutical companies, researchers, and health authorities seek faster, more cost-effective pathways to address unmet medical needs. Traditional drug development can take over a decade and cost billions, with high rates of clinical failure. In contrast, repurposed drugs have already cleared significant safety and pharmacokinetic hurdles, enabling developers to bypass early-stage trials and significantly reduce time to market. This has made repurposing a highly attractive strategy, particularly in areas like rare diseases, oncology, neurodegenerative disorders, and infectious diseases.

The COVID-19 pandemic further propelled interest in repurposing, as drugs like remdesivir, dexamethasone, and hydroxychloroquine were rapidly evaluated for efficacy against SARS-CoV-2. The crisis showcased how regulatory bodies could fast-track repurposed drugs through Emergency Use Authorizations (EUAs), highlighting a new precedent for accelerated pathways. Furthermore, the success of drugs such as thalidomide (reintroduced for multiple myeloma) and sildenafil (originally developed for hypertension, now widely used for erectile dysfunction) have demonstrated the broad clinical and commercial value of this strategy. These examples underscore why drug repurposing is increasingly viewed as a vital component of modern pharmaceutical R&D.

What Are the Emerging Trends Transforming the Drug Repurposing Landscape?

A major trend reshaping the repurposing market is the integration of artificial intelligence (AI) and machine learning (ML) into drug discovery pipelines. Computational models can now analyze massive datasets-ranging from genomic data to real-world evidence and electronic health records-to identify novel drug-disease relationships. AI-driven platforms are enabling in silico screening of compound libraries to prioritize candidates for preclinical and clinical evaluation. This is especially impactful in rare disease treatment and precision oncology, where traditional pipelines often struggle due to limited patient populations and high R&D costs.

Collaborative consortia and public-private partnerships are also on the rise. Initiatives like the NIH’s NCATS (National Center for Advancing Translational Sciences) and Open Targets are pooling data and resources across academia, industry, and government to accelerate repurposing efforts. Additionally, patent expiration of blockbuster drugs is fueling new interest in repurposing by generics and specialty pharma companies. Regulatory frameworks are evolving too-efforts to provide clearer guidance for 505(b)(2) approvals in the U.S. and adaptive licensing models in Europe are making it easier to navigate the intellectual property and clinical validation landscape. These trends are creating fertile ground for innovation, collaboration, and accelerated drug development across disease areas.

Which Therapeutic Areas Are Benefiting Most from Repurposing Strategies?

The impact of drug repurposing is most visible in complex and underserved therapeutic areas. In oncology, for instance, repurposed drugs are being explored as adjuvants or second-line treatments. Metformin (a diabetes drug), propranolol (a beta-blocker), and itraconazole (an antifungal) have shown anticancer potential in various studies. In neurodegenerative diseases like Alzheimer’s and Parkinson’s, drugs targeting inflammation, cholesterol metabolism, and mitochondrial function are being repositioned to slow disease progression-areas where novel therapies have struggled. This repurposing model offers new hope in high-failure domains by leveraging known pharmacodynamics to target secondary pathways.

In infectious diseases, especially with rising antimicrobial resistance (AMR), repositioned antivirals and antibiotics are filling critical gaps. For example, certain anticancer agents have shown unexpected antibacterial or antifungal effects, while psychiatric drugs are being investigated for their immunomodulatory roles in viral infections. Autoimmune and inflammatory diseases, including lupus, rheumatoid arthritis, and multiple sclerosis, also stand to benefit, as researchers uncover overlapping pathways with other disease classes. Even mental health treatments are seeing cross-utility-ketamine’s use in treatment-resistant depression is a prime example. These cross-therapeutic applications are broadening the value proposition of many legacy drugs, supporting their reintegration into modern treatment paradigms.

What Is Driving Growth and Strategic Investment in Drug Repurposing?

The growth in the drug repurposing market is driven by several factors related to technological enablement, regulatory facilitation, and evolving pharmaceutical strategies. AI and bioinformatics platforms are significantly improving the success rate of repurposing projects by predicting mechanisms of action and identifying off-target effects with high precision. The availability of large-scale biomedical datasets-including omics profiles, disease registries, and patient-level data-provides fertile ground for cross-indication mapping and drug efficacy modeling. These technologies reduce the risk, cost, and time traditionally associated with de novo drug development.

End-use adoption is also accelerating. Biotechnology firms are increasingly pursuing repurposing as a core business model, while large pharma companies are integrating repurposing into life-cycle management to extend the value of off-patent or low-performing assets. Regulatory bodies are introducing streamlined pathways for approvals-such as the 505(b)(2) route in the U.S.-which allows developers to leverage existing safety and efficacy data while only requiring supplemental clinical evidence for new indications. This has created a favorable environment for licensing, joint ventures, and venture capital investment in repurposing ventures. Furthermore, patient advocacy groups and rare disease foundations are lobbying for and funding repurposing studies, driving both awareness and clinical momentum. These combined forces are ensuring that drug repurposing remains a strategic and rapidly growing pillar in the global pharmaceutical innovation ecosystem.

SCOPE OF STUDY:

The report analyzes the Drug Repurposing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Indication (Oncology, CNS Diseases, Neurodegenerative Diseases, Other Disease Indications); Approach Type (Disease-Centric Approach, Target-Centric Approach, Drug-Centric Approach); End-Use (Hospitals & Clinics, Ambulatory Surgery Diseases, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Algernon Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • BioXcel Therapeutics Inc.
  • Bristol-Myers Squibb Co.
  • Every Cure
  • Exscientia Ltd.
  • GSK plc
  • Healx Ltd.
  • Johnson & Johnson
  • Melior Discovery
  • Novartis AG
  • Pfizer Inc.
  • Rejuvenate Biomed NV
  • Retrotope Inc.
  • SOM Biotech S.L.
  • Tonix Pharmaceuticals
  • United Therapeutics Corp.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Drug Repurposing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Cost-Efficiency Advantages of Drug Repurposing Accelerate R&D in Rare and Neglected Diseases
    • Growing Pressure to Reduce Development Timelines Spurs Interest in Repurposing Existing Molecules
    • Advancements in Bioinformatics and AI Algorithms Propel Discovery of New Indications for Known Drugs
    • Surging Demand for Affordable Therapeutics Drives Market Expansion for Repurposed Drug Candidates
    • Pharma Industry Shift Toward Risk Minimization Supports Investment in Drug Repositioning Portfolios
    • Increased FDA Approvals of Repurposed Drugs Validate Regulatory Pathways and Business Models
    • Pandemic-Driven Focus on Fast-Track Therapies Propels Global Awareness of Drug Repurposing Benefits
    • Integration of Omics Technologies and Patient Data Analytics Enhances Target Identification
    • Partnerships Between Biotech Startups and Academic Institutions Accelerate Pipeline Development
    • AI-Powered Drug Repurposing Platforms Expand Addressable Market Across Chronic Conditions
    • Growing VC Funding in Life Sciences Strengthens Commercial Viability of Repurposing Models
    • Patent Expiry Pressures Encourage Pharma Companies to Extend Value of Existing Assets via New Indications
    • Increased Public and Private Grant Support for Rare Disease Therapies Fuels Repurposing Projects
    • Surging Demand for Personalized Therapies Promotes Indication-Specific Repurposing Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Drug Repurposing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Drug Repurposing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for CNS Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for CNS Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for CNS Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ambulatory Surgery Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ambulatory Surgery Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Ambulatory Surgery Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Disease-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Disease-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Disease-Centric Approach by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Target-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Target-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Target-Centric Approach by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Drug-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Drug-Centric Approach by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Drug-Centric Approach by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • JAPAN
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • CHINA
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • EUROPE
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Drug Repurposing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • FRANCE
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • GERMANY
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Drug Repurposing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • INDIA
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Drug Repurposing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Drug Repurposing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Drug Repurposing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030
  • AFRICA
    • Drug Repurposing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Drug Repurposing by Disease Indication - Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Drug Repurposing by Disease Indication - Percentage Breakdown of Value Sales for Oncology, CNS Diseases, Neurodegenerative Diseases and Other Disease Indications for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Drug Repurposing by End-Use - Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Drug Repurposing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Ambulatory Surgery Diseases for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Drug Repurposing by Approach Type - Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Drug Repurposing by Approach Type - Percentage Breakdown of Value Sales for Disease-Centric Approach, Target-Centric Approach and Drug-Centric Approach for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제